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Abstract  
Background: Pancreatic mucinous cystic neoplasms MCNs are rare mucin-producing cystic 
tumours defined by the presence of ovarian-type stroma. MCNs have a malignant potential 
and thus surgery is frequently performed. In this cohort study we aim to better define the 
criteria for surgical resection in MCN. 
Methods: This multicentre retrospective study included all resected MCNs between 2003-
2015 in participating centres. Lesions without ovarian-type stroma were excluded. Patient 
characteristics, preoperative findings, histopathology and follow-up data were recorded. 
Results: The study included 211 patients. Median age was 53 (range 18–82) years and 95.7 
per cent (202 of 211) occurred in women. Median pre-operative tumour size was 55 (range 
12-230) mm. Thirty-two of the 211 (16.1 per cent) were malignant and high-grade dysplasia 
(HGD) was found in a further 6.2 per cent (n=13). A third of MCNs in men were associated 
with invasive cancer compared to 15.3 per cent in women. Five cases of malignant 
transformation occurred in MCNs <4cm. All cases of malignancy or HGD were associated 
with symptoms or features of concern on pre-operative cross-sectional imaging. On 
multivariate analysis, raised CA19-9 (OR 10.9; 95 per cent confidence interval (c.i.):1.9–24.5 
p<0.001), mural nodules (OR 6.9; 95 per cent c.i..:1.3–36.1, p=0.023), weight loss (OR 2.7; 
95 per cent c.i.:1.5–14.6, p=0.004) and tumour size (OR 1.019; 95 per cent c.i.: 1.0–1.0, 
p=0.020) were independent factors, predictive of malignant transformation. 
Conclusions: Small indeterminate MCNs without symptoms or features of concern may 








MCNs are neoplastic cystic tumours of the pancreas, which have the potential to evolve into 
an invasive cancer. They have been classified separately from IPMNs by the World Health 
Organization (WHO) since 1996,1  and the Armed Forces Institute of Pathology (AFIP) from 
1997.23 Pancreatic mucinous cystic neoplasms are defined as well-demarcated cystic lesions, 
lined by a mucin-producing columnar epithelium overlying an ovarian-type stroma.1 
Although MCNs are relatively rare tumours, the overall incidence of Pancreatic Cystic 
Neoplasms is increasing.2-4 MCN are estimated to account for between 10-45% of all resected 
pancreatic cysts.5, 6 
 Although MCN are classified as neoplastic lesions7 their actual malignant potential 
remains uncertain, with rates of associated invasive cancer ranging anywhere between 0 and 
34% in the current literature.8 Associated malignancy was substantially higher in older 
studies, but these series included many larger lesions and lesions classified prior to the latest 
WHO pathological criteria for MCN, so may have inadvertently incorporated a proportion of 
intraductal papillary mucinous neoplasms (IPMN), potentially explaining the higher rates of 
malignancy observed.9 Recent publications from single centres have suggested that malignant 
transformation in MCN may actually be rare, especially when the tumours are small in size 
(<4cm).10-16 
 The current management of a pancreatic cystic neoplasms is defined by a number of 
consensus guidelines from the International Association of Pancreatology (IAP),17 European 
expert consensus statement on cystic tumours of the pancreas,18 and the American 
Gastroenterology Association.19 The IAP and European guidelines specifically mention the 
management of MCN and both stipulate that where the diagnosis is certain and the patient is 
an operative candidate then surgical resection should be performed. Within the European 
consensus statement on cystic lesions of the pancreas, there is a proviso that where the 
diagnosis is uncertain, and there are no associated worrisome features and the lesion is less than 
4cm, then surveillance may be appropriate. However, to date very few studies have described 
the natural history of small MCN to support this management strategy and no one has validated 
the current recommendation within the European guidelines. 
 As the guidelines for MCN to date have primarily advocated surgical resection, very 
few studies have described which worrisome features would predict malignant transformation 
if these lesions were to be surveyed. With the exception of a recent systematic review20 and a 
single multi-institution US study,21 worrisome features in MCN have been drawn from small 
 
5 
singe centre experiences or extrapolated from findings in IPMN. Further large patient cohorts 
that have undergone careful classification and long-term follow up are therefore needed to 
better inform the natural history and optimal criteria for surgical resection of these lesions. 
The aim of this large multi-institution European study was to determine the rate of associated 
malignancy in resected MCN, define which clinical and radiological features predicted 
malignant transformation and validate the management guidelines for MCN proposed by the 
European consensus statement on pancreatic cystic neoplasms. 
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Patients and methods  
Setting and study design 
A multicentre retrospective, observational study from nine pancreatic centres from across 
Europe [Supplementary Table 1]. The study was conducted in accordance with STROBE 
guidelines for case-control studies. 
 
Ethics 
The study protocol was reviewed and ethical approval obtained from the local review board 
in each centre. In the UK the Health Research Authority deemed the study to be primarily an 
audit of current practice and therefore formal ethical review was not required. The study 
protocol conforms to the ethical guidelines of the Declaration of Helsinki. 
 
Inclusion criteria 
All consecutive patients with a histologically confirmed MCN of the pancreas resected 
between January 1st 2003 and December 31st 2015 in each participating centre. Cases were 
identified though individual unit’s pancreatic cyst databases, multidisciplinary team meeting 
records and pathology records.  
 
Exclusion Criteria 
After a local review of the pathology report any patients with an MCN without ovarian-type 
stroma were excluded from the study. 
 
Data Recorded 
For each patient, the medical records were reviewed in each centre and the following 
information, where available, was recorded in the study spreadsheet: name of hospital, 
gender, age at diagnosis and medical history, American Society of Anaesthesiology (ASA) 
score, diabetes, smoking, previous pancreatic disease, previous cancer, family history of 
cancer.  
Any associated symptoms were also recorded; an MCN was defined as symptomatic 
when identified on imaging performed for the evaluation of abdominal or back pain, 
obstructive jaundice, acute/recurrent pancreatitis or any documented history of recent weight 
loss. The following preoperative blood tests, when undertaken, were recorded; amylase, 
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serum carcinoembryonic antigen (CEA; normal range <4.0 ng/mL), serum carbohydrate 
antigen 19-9 (CA 19-9; normal range <37 U/mL).  
Radiological data recorded included type of scan; ultrasound, computed tomography 
(CT), magnetic resonance cholangiopancreatography (MRCP), endoscopic ultrasound (EUS), 
fine needle aspiration (FNA). From the cross-sectional imaging (CT or MRI/MRCP), the 
following features were recorded: lesion size (maximal dimension), location and number of 
cystic lesions, presence of a solid component (mural nodules, solid component, calcification 
of the cyst or the wall, wall thickening), presence of septations, features of acute or chronic 
pancreatitis, and dilatation of the main pancreatic duct to >6mm (upstream of the cyst) or 
biliary tree dilatation. For patients undergoing EUS-FNA, cytology and cyst fluid 
biochemistry (CEA and amylase) results were also recorded.  
Operative details recorded included date of surgery and type of resection, post-
operative adverse events (according to Clavien-Dindo grading),22 30-day mortality, final 
histology, length of follow-up (time from surgery to the last MCN-related or other relevant 
outpatient appointment), follow-up imaging data and evidence of recurrence.  
 
Histopathological analysis 
The diagnosis of an MCN was confirmed locally in each centre. Presence of ovarian type 
stroma was considered mandatory for the diagnosis and inclusion in the study. In cases where 
the original report was inconclusive and in all male patients a second review by an 
experienced local pancreatic pathologist was performed to confirm the diagnosis. Dysplasia 
was classified in accordance with the most aggressive histological epithelial changes as 
defined by the World Health Organization (WHO) classification system.7 Tumours were 
graded as having low or intermediate grade dysplasia, high-grade dysplasia including 
carcinoma in situ, and malignant when invasive carcinoma was present.7 
 
Statistics 
All statistical analyses were performed using SPSS version 22.0 (SPSS Inc., Chicago, IL, 
USA). In the tables, “n” indicates the number of patients with available data. Chi-square or 
Fisher's exact test was applied for analysis of categorical variables. Median values and inter-
quartile ranges were considered for continuous variables. The non-parametric Mann-Whitney 
test was used to compare continuous variables. Multiple logistic regression models were used 
to identify independent factors for malignant transformation. Long-term survival was 
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analysed using Kaplan Meier log rank analysis. All tests were two-tailed and a P-value < 





Two hundred and eleven patients with a histologically confirmed surgically resected MCN 
were included in the study. Median age at the time of surgery was 53 (range 18–82) years and 
95.7 per cent (202/211) were women. Sixty three percent of the patients were symptomatic 
and in 37 per cent the diagnosis was made incidentally during abdominal cross-sectional 
imaging performed for other reasons. Ninety percent of patients were investigated with CT 
with the remainder having an MRI/MRCP. Twenty eight percent of patients had both a CT 
and MRI. On pre-operative imaging, the median tumour size was 55 (range 12-230) mm and 
an MCN was suspected clinically in 49.7 per cent (73/147), an IPMN in 11.6 per cent 
(17/147) and the diagnosis remained uncertain in 38.8 per cent (57/147) of the cases. Mural 
nodules were present in 23.4 per cent, cyst wall calcification in 18.8 per cent and septations 
in 52.9 per cent of the cases. In 8.8 per cent the diameter of the main pancreatic duct was ≥6 
mm (upstream of the cyst) [Table1]. In addition to cross-sectional imaging by CT or MRI 39 
per cent of patients had an EUS and an FNA was performed in 28% of patients. Cytology had 
a sensitivity, specificity, positive predictive value and negative predictive value of 66.7 per 
cent, 98.1 per cent, 66.7 per cent, 98.1 per cent respectively for malignant transformation. 
 
A distal pancreatectomy was performed in 82.9 per cent, pancreatoduodenectomy in 8.5 per 
cent and an enucleation in 4.3 per cent. Mortality at 30-days was 0.9 per cent. 30-day 
morbidity was 37.9 per cent; classified as Clavien-Dindo Grade 1 in 10.4 per cent, Grade 2 in 
15.2 per cent, Grade 3 in 9.5 per cent and Grade 4 in 1.9 per cent. 
 
The median resected tumour size was 55.5 (range 20-300) mm. Invasive cancer was present 
in 16.1 per cent (34/211), with high-grade dysplasia (HGD) seen in a further 6.2 per cent 
(13/211) of patients. For patients with invasive MCN cancer, the tumour was classified as 
stage Ia in 9 (26.5 per cent) patients, stage Ib in 8 (23.5 per cent), stage IIa in 6 (17.6 per 
cent), stage IIb in 6 (17.6 per cent) and stage III in 5 (14.7 per cent) patients. Malignant 
transformation was associated with presence of symptoms (88.2 vs. 58.2 per cent; p=0.001), 
especially in those presenting with pancreatitis (26.5 vs. 9.6 per cent; p=0.018), jaundice 
(20.6 vs. 1.7 per cent; p<0.0001), or who had significant weight loss (32.3 vs. 6.2 per cent; 




The rate of invasive cancer correlated with increasing tumour size [Figure 1a]. In lesions 
greater than 12 cm the rate of invasive cancer was 30 per cent, compared to just 5 per cent in 
lesions 3.0-3.9 cm and 6 per cent in lesions 0-2.9 cm. When stratified by sex the rate of 
malignancy in lesions less than 3cm in female patients decreased to 3 per cent (HGD 3 per 
cent) compared to 25 per cent in men (HGD 25 per cent) [Figure 1b and c]. All patients with 
malignant lesions or HGD, regardless of tumour size had symptoms or one or more feature of 
concern on cross-sectional imaging [Table 4]. 
On univariate analysis, we found that presence of symptoms, previous pancreatitis, 
jaundice, raised Ca19-9, recent weight loss, tumour size and mural nodules were significant 
risk factors predictive of invasive cancer. On multivariate analysis, raised CA19-9 (OR 10.5; 
95 per cent c.i.: 2.9-18.2, p<0.001), mural nodules (OR 3.6; 95 per cent c.i.: 1.3-20.6, 
p=0.002), weight loss (OR 3.4; 95 per cent c.i.:2.3–12.3, p=0.034) and tumour size (OR 4.2; 
95 per cent c.i.: 3.0–11.0, p=0.001) remained independent factors of malignant 
transformation. The model was a good predictor of malignant transformation with 
Nagelklerke R Square value of 0.7 [Table 3]. 
Median survival for patients with a malignant MCN was 44 months (range 0-167 
months), 12 patients died during follow up of which 10 was due to disease recurrence. A non-
significant but notable difference in survival was also observed between men and women 





In this large cohort of patients, resected after the introduction of the new pathological 
classification of MCN, the overall rate of associated invasive cancer was low; 16.1% 
compared to up to 34% in some earlier publications.8 Rates of HGD were lower than in other 
single centre series 12, 13, 16 at 6.2% but similar to the rate found in a recent multicentre study 
from North America.21  
 In clinical practice, differentiating MCN from other uni- and oligocystic tumors (i.e. 
branch duct-IPMN and serous cystadenoma) remains a significant challenge, as to date 
features which predict invasive malignancy in MCN have been poorly characterised and 
often overlap with other cystic lesions of the pancreas.24 When pancreatic cysts are small the 
diagnosis can be especially difficult as many of the typical radiological features (i.e. 
communication with the main pancreatic duct in case of BD-IPMNs) are not present. The 
pre-operative uncertainty in defining these lesions was clearly reflected in this study, with 
less than half of MCN being correctly classified prior to resection. Current guidelines are 
clear and consistent when the diagnosis of MCN is certain, recommending surgical resection 
in all patients. However when the pre-operative diagnosis is less clear, as in a large 
proportion of cases in this study, the European guidelines have suggested that if the lesion is 
small in size (<4cm) and is without worrisome features, then a period of surveillance may be 
appropriate to better define the diagnosis prior to surgery. However, few studies have 
explored the natural history of MCN to support the safely of this proposed management 
strategy.18 
Over the last three decades the size at which MCN are detected has decreased.20 
Given that features of concern are often absent in small lesions, cyst diameter has remained 
the most important radiologic predictor of malignant transformation. At what size of MCN 
patients should be referred for surgical resection remains uncertain. In this large cohort study, 
invasive cancer occurred in 9.8% of lesions less than 4cm and 5.3% less than 3cm. In the five 
cases of invasive cancer in lesions less than 4cm [Table 4], as well as all cases of cancer or 
HGD in this study, at least one pre-operative worrisome feature was present to prompt 
surgical resection. When stratified by sex the rate of associated invasive cancer in women 
with lesions less than 4cm was 5.5% and in lesions less than 3cm was just 2.9%.  Although 
this retrospective data was drawn from surgically resected cases and will need to be 
confirmed by prospective surveillance studies, these findings do suggest that the 
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conservative management of indeterminate cystic lesions which are probably an MCN, is 
feasible, as advocated by the European guidelines. Particularly in small lesions (<4cm), 
occurring in women without worrisome features. 
MCN differ from other pancreatic cystic neoplasms, by predominantly occurring in 
female patients. Whether MCN, defined by the presence of ovarian-type stroma, can even 
occur in male patients has been debated,25 but a number of cases in male patients have been 
described.12, 13, 16 In this study with careful pathological characterization, just 4.3% of MCN 
occurred in men, one of the lowest rates reported to date. Rates of invasive cancer and high-
grade dysplasia were also much more common in men than women and appeared to occur at 
an earlier stage when the lesions were still small in size [Table 2].  
 In the multivariate analysis, in addition to tumour size, this study also found that a 
raised CA 19-9 and a solid component were also independent predictors of invasive cancer. 
This supports the findings of other studies which have also found that CA19-9,13, 21 and the 
presence of a solid component or a mural nodule to be reliable predictors of invasive 
malignancy in MCN.10, 13, 15, 16, 24, 26   
 The survival of patients with a malignant MCN is superior to pancreatic ductal 
adenocarcinoma.6 A non-significant difference in survival was also observed between male 
and female patients, which although unexpected, perhaps further supports the more 
aggressive behavior MCN observed in male patients in this cohort and others.21 In other 
female predominant pancreatic cystic neoplasms, such as solid pseudopapillary tumours, 
male patients have also been observed to have a poorer prognosis.28 All cases of malignancy 
were solely seen in MCN with symptoms or worrisome features, regardless of tumour size. A 
raised CA19-9, a solid component, weight loss or large tumour size (≥4cm) predicted 
malignant transformation in these lesions. Therefore in small indeterminate lesions without 
symptoms or features of concern, a more conservative approach is potentially feasible, as 
advocated in the European consensus statement on cystic tumours of the pancreas. 
 This study has several strengths; it analyses a large cohort of carefully characterized 
patients with a pathologically confirmed MCN, where ovarian-type stoma was present in all 
cases. The dataset includes comprehensive demographic, clinical, radiological, surgical, 
pathological and follow-up data, which has allowed us to better define features, which predict 
malignant transformation. Potential limitations include that most cases have been recruited 
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from tertiary referral centres, so the proportion of high-risk lesions and malignant cases may 
be higher. Large community based cohorts and surveillance cohorts of pancreatic cystic 
neoplasms have reported much lower incidences of associated malignancy.29 However 
without being able to pathologically define MCN lesions it would be impossible to carry out 
this study in this group. Some patients included in the study may have been included in 
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Table 1. Characteristics and radiological features of study cohort 
 % n 
Demographics and clinical symptoms    
Sex 
 Female 







Age, years median (interquartile range)  53 (43-63) 
BMI*, kg/m2 median (interquartile range)  25 (23-29) 
Presence of symptoms 
 Abdominal pain 
 Acute or recurrent pancreatitis 












Pre-operative radiological features   
Location 
 Head/uncinate process 
 Body 
 Tail 











Median tumour size, mm (interquartile range)  55 (30-91) 
Mural nodules 23.4 37/158 
Cyst wall calcification 18.8 32/170 
Dilated main pancreatic duct  8.8 14/159 
Septations 52.9 83/157 
Surgery performed and outcomes   
Type of surgery 
















30-day adverse events 37.9 80/211 
Peri-operative 30-day mortality 0.9 2/211 
Presence of invasive cancer 16.1 34/211 
* BMI Body Mass Index. ** Includes total pancreatectomies and multi-visceral resections.
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Table 2. Features of benign and malignant MCN stratified by sex. 
 
 All patients (n=211) Female (n=202) Male (n=9) 
 Patients with 
invasive cancer 




































Risk factors, clinical symptoms and serum tumour markers 





55 (44-66) 52 (43-62) 0.349 53 (43-64) 51 (43-61) 0.565 68 (64-68) 70 (60-79) 0.905 




25 (23-28) 26 (23-29) 0.732 25 (23-29) 25 (23-30) 0.943 24 (22-24) 27 (24-28) 0.250 
Diabetes 
mellitus 
1 (3.3) 14 (8.5) 0.475 1 (3.7) 12 (7.5) 0.696 0 (0.0) 2 (33.3) 0.50 
Presence of 
symptoms  
30 (88.2) 103 (58.2) 0.001 27 (87.1) 98 (57.3) 0.001 3 (100.0) 5 (83.3) 1.000 
Jaundice  7 (20.6) 3 (1.7) 
<0.00
1 
5 (16.1) 2 (1.2) 0.001 2 (66.7) 1 (16.7) 0.226 
History of 
pancreatitis  








0 (0) 8 (4.5) 0.360 0 (0) 8 (4.7) 0.611 0 (0) 0 (0) 1.000 
Recent weight 
loss  
11 (32.4) 11 (6.2) 
<0.00
1 
8 (25.8) 10 (5.8) 0.002 3 (100.0) 1 (16.7) 0.048 
Raised serum 
Ca19-9 
11 (68.8) 13 (16.0) 
<0.00
1 
9 (69.2) 13 (16.9) <0.001 2 (66.7) 0 (0.0) 0.143 
Cross-sectional imaging features 




100 (45-131) 52 (30-85) 0.001 111 (54-133) 52 (30-86) <0.001 30 (28-30) 33 (17-49) 0.714 
Mural nodules  12 (60.0) 25 (18.1) 
<0.00
1 
10 (58.8) 22 (16.5) <0.001 2 (66.7) 3 (60.0) 0.741 
Dilation of the 
main 
pancreatic duct 
4 (21.1) 10 (7.1) 0.067 3 (18.8) 7 (5.2) 0.074 1 (33.3) 3 (60.0) 1.000 
Septations  12 (57.1) 71 (52.2) 0.815 10 (55.6) 70 (53.4) 1.000 2 (66.7) 1 (20.0) 0.464 
Cyst wall 
calcification  
7 (35.0) 25 (19.4 0.142 6 (35.3) 24 (19.4) 0.201 1 (33.3) 1 (20.0) 1.000 
Head location 7 (20.6) 16 (9.0) 0.067 4 (12.9) 13 (7.6) 0.304 3 (100) 3 (50) 0.464 
CBD dilatation 4 (18.2) 4 (3.0) 0.014 2 (10.5) 3 (2.3) 0.122 2 (66.7) 1 (20.0) 0.464 
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Data are presented as absolute number (percentage) unless otherwise indicated. BMI: Body Mass Index CBD: Common Bile Duct
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Table 3. Binary logistic regression of preoperative risk factors for invasive adenocarcinoma 
arising from a MCN 
 
Variable Univariate analysis  Multivariate analysis 
Clinical features OR (95% CI) 
p 
value 
 OR (95% CI) 
p 
value 








History of pancreatitis 3.39 (1.36-8.43) 0.009 
 
 NS 
Jaundice 15.04 (3.66-61.71) <0.001 
 
 NS 
Weight loss 7.22 (2.81-18.53) <0.001 
 
3.40 (2.34-12.34) 0.034 
Serum Ca19-9 11.51 (3.42-38.68) <0.001 
 
10.54 (2.85-18.23) <0.001 
Tumour size * 5.09(1.47-17.61) 0.010 
 
4.23 (3.02-11.03) 0.001 
Tumour location: 
Head of pancreas 
2.61 (0.98-6.93) 0.054 
 
 NS 
Solid component 6.78 (2.51-18.32) <0.001 
 
3.55 (1.31-20.55) 0.002 
Dilation of main 
pancreatic duct 
3.47 (0.97-12.43) 0.056 
 
 NS 

















Supplementary Table 1.  Age, sex, worrisome features associated with invasive MCNs 
of less than 4cm  
 
 Age Sex Tumour size Worrisome features 
Case 1 74 F 33 Symptoms, raised Ca 19-9, dilated main PD 
Case 2 70 M 28 
Symptoms, raised Ca 19-9, mural nodules, 
cyst wall calcification, septations 
Case 3 37 F 35 Symptoms, mural nodules 
Case 4 64 M 30 
Symptoms, raised Ca 19-9, septations, dilated 
CBD 
Case 5 65 F 16 Symptoms 
 






Tampere University Hospital Finland 47 22.3 








Department of Surgery, Karolinska 
University Hospital 
Sweden 30 14.2 
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Miguel Servet University Hospital, 
Zaragoza 
Spain 15 7.1 
Chirurgische Klinik, Klinikum rechts 
der Isar, Technische Universität 
München 
Germany 13 6.2 
Ciudad Real University Hospital Spain 8 3.8 




Figure 1a. Percentage of associated invasive cancer at different tumour sizes  
 
 









Figure 2.  Kaplan-Meier curve for patients undergoing surgical resection for 
invasive MCNs in men and women (n=34) 
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P=0.13
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